Success Metrics

Clinical Success Rate
92.3%

Based on 12 completed trials

Completion Rate
92%(12/13)
Active Trials
2(13%)
Results Posted
83%(10 trials)
Terminated
1(6%)

Phase Distribution

Ph phase_4
3
19%
Ph phase_3
8
50%
Ph phase_2
4
25%

Phase Distribution

0

Early Stage

4

Mid Stage

11

Late Stage

Phase Distribution15 total trials
Phase 2Efficacy & side effects
4(26.7%)
Phase 3Large-scale testing
8(53.3%)
Phase 4Post-market surveillance
3(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

12 of 14 finished

Non-Completion Rate

14.3%

2 ended early

Currently Active

2

trials recruiting

Total Trials

16

all time

Status Distribution
Active(2)
Completed(12)
Terminated(2)

Detailed Status

Completed12
Terminated1
Withdrawn1
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
2
Success Rate
92.3%
Most Advanced
Phase 4

Trials by Phase

Phase 24 (26.7%)
Phase 38 (53.3%)
Phase 43 (20.0%)

Trials by Status

terminated16%
withdrawn16%
completed1275%
active_not_recruiting16%
recruiting16%

Recent Activity

2 active trials
Showing 5 of 16
recruitingphase_3

Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor

NCT05834777
active_not_recruitingphase_2

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

NCT04488081
completed

A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema

NCT05509569
completedphase_4

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2

NCT04113109
completedphase_2

Inhibition of Bradykinin in COVID-19 Infection With Icatibant

NCT05407597
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT05834777Phase 3

Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor

Recruiting
NCT04488081Phase 2

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Active Not Recruiting
NCT05509569

A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema

Completed
NCT04113109Phase 4

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2

Completed
NCT05407597Phase 2

Inhibition of Bradykinin in COVID-19 Infection With Icatibant

Completed
NCT00997204Phase 3

EASSI - Evaluation of the Safety of Self-Administration With Icatibant

Completed
NCT00912093Phase 3

A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)

Completed
NCT00500656Phase 3

Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)

Completed
NCT00097695Phase 3

Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema

Completed
NCT01919801Phase 3

Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema

Completed
NCT01386658Phase 3

A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema

Completed
NCT03888755Phase 3

A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants

Completed
NCT03177798Phase 2

Mitochondria and Chronic Kidney Disease

Completed
NCT03005184Phase 2

Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2

Withdrawn
NCT01574248Phase 4

Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema

Terminated
NCT01457430Phase 4

Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16